COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating
the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in
combination with nivolumab.